Introduction {#Sec1}
============

In many countries, prenatal diagnosis by chorionic villus sampling or amniocentesis is routinely offered to pregnant women who have an increased risk of carrying a child with a chromosomal abnormality. Amniocentesis is the most commonly used invasive prenatal diagnostic procedure in western countries and is performed in about one in 30 pregnancies \[[@CR1], [@CR2]\].

Karyotyping is considered the reference test to detect fetal genetic abnormalities in amniotic fluid cells with considerable accuracy \[[@CR3], [@CR4]\]. However, it is labor-intensive and the costs are high. Furthermore, obtaining results takes 2--3 weeks and the extensive detection capacity of karyotyping can be perceived as a disadvantage due to the detection of abnormalities with unclear or mild clinical relevance, causing difficult counseling issues, patient anxiety, emotional dilemmas concerning the continuation of pregnancy and, albeit rare, unwarranted pregnancy terminations \[[@CR5], [@CR6]\].

Due to these disadvantages, karyotyping as a routine test has been challenged for relatively low-risk indications. In 2003, a molecular PCR-based technique, multiplex ligation-dependent probe amplification (MLPA) became available to detect fetal aneuploidies in amniotic fluid cells \[[@CR7]\]. Following the results of preclinical laboratory studies, MLPA has been proposed as a promising alternative for the detection of the most common chromosomal aneuploidies, i.e. trisomy 13, 18, 21 and sex chromosome aneuploidies. Compared to karyotyping, MLPA has several potential advantages; the waiting time for test results is reduced with simultaneous reduction of anxiety, the preceding prenatal counseling process can focus on the most common chromosomal aneuploidies, and the technique is considerably less labor-intensive and more suitable for high-throughput testing, thereby exploiting economies of scale.

Nowadays, much effort has been put into priority setting based on a trade-off of costs and health gains. From an economic perspective, the preferred prenatal diagnostic strategy is the one that overall yields favorable health gains relative to associated cost differences \[[@CR8]\].

In order to compare the MLPA and karyotyping strategies in terms of diagnostic accuracy, health-related quality of life and cost-effectiveness, we initiated a prospective diagnostic study comparing MLPA with karyotyping in routine clinical practice; the MLPA And Karyotyping, an Evaluation (MAKE) study (ISRCTN47252164) \[[@CR9]\]. If MLPA has comparable diagnostic accuracy and is able to reduce maternal anxiety and costs in routine clinical practice, MLPA could present a suitable substitute for karyotyping. Our research question was: what are the costs and effects of MLPA compared to karyotyping when applied to the indications advanced maternal age, increased risk following prenatal screening and anxiety?

Materials and methods {#Sec2}
=====================

Clinical study {#Sec3}
--------------

The clinical MAKE study was set up as a prospective nationwide cohort study enrolling 4,585 consecutive women undergoing amniocentesis for advanced maternal age (≥36 years), increased risk following prenatal screening or anxiety. Other referral indications were excluded (e.g. ultrasound abnormalities) since these are associated with an increased risk of a chromosomal abnormality other than trisomies 13, 18, 21 and sex chromosome abnormalities. Details of the study design have been published elsewhere \[[@CR9], [@CR10]\]. In summary, after obtaining informed consent, amniocentesis was carried out by specifically trained obstetricians. All amniotic fluid samples were tested with both MLPA and karyotyping, allowing a pair-wise comparison of MLPA and the reference test; karyotyping. Sample size was estimated to demonstrate non-inferiority (i.e. comparable diagnostic accuracy) of MLPA to karyotyping. During a pre-trial meeting, experts in prenatal diagnosis, clinical epidemiology and statistics agreed on a critical non-inferiority margin of 0.002. At least 4,497 paired test results were needed (one-sided alpha 0.05, power 0.90) to be able to reject the null hypothesis that MLPA is inferior to karyotyping.

MLPA {#Sec4}
----

DNA was isolated from 1--8 ml uncultured amniotic fluid samples, depending on the total amount of amniotic fluid received. DNA was isolated from amniotic fluid cells through lysis of cell pellets and proteinase K treatment using standard procedures. This DNA was purified using a QIAamp kit (Qiagen, Germany) according to the manufacturer's instructions. MLPA samples were analyzed with the commercially available SALSA MLPA P095 kit (MRC Holland, the Netherlands). For each genomic target, a set of two probes is designed to hybridize immediately adjacent to each other on the same target strand. Both probes consist of a short target sequence and a universal polymerase chain reaction (PCR) primer-binding site. One of the probes contains a stuffer sequence with a unique length and sequence. Following hybridization, each pair of adjacent probes is joined by a ligation reaction. Next, PCR is performed using a fluorescent-labeled primer pair, which ensures that the relative yield of each of the PCR products is proportional to the amount of each of the target sequences. The different length products are separated on an automated capillary sequencer. The size and peak areas for each probe are quantified and analyzed by data analyzing software (GeneMarker, SoftGenetics, LLC, State College, PA, USA, or Genescan and Genemapper version 3.7/4.0, Applied Biosystems, CA, USA)\[[@CR7]\]. Relative probe signals are calculated and compared with samples of normal male and female sex. In chromosomally normal samples, the relative probe signal is expected to be 1 for all probes. A normal value is defined as a relative probe signal between 0.7 and 1.3. A relative probe value of \<0.7 indicates a monosomy, whereas a relative probe value of \>1.3 indicates a trisomy. Technicians had a molecular genetics or a cytogenetics background; all were trained in the execution of MLPA prior to the study onset. MLPA was performed in duplicate, provided that at least 2 ml of amniotic fluid was available. All eight genetic centers have different sample throughput, depending on the number of patients in their referring prenatal diagnostic centers.

Karyotyping {#Sec5}
-----------

Fetal cells were cultured and karyotyped after banding. Routinely, metaphases of at least ten colonies were investigated. All centers followed national quality guidelines but minor differences in the number of cell colonies cultured, chromosome banding and reporting of the results were allowed \[[@CR11]\].

Economic analysis framework {#Sec6}
---------------------------

The economic analysis was performed from the societal perspective which means that all significant costs and health effects both in the short and long term should be considered, regardless of who experiences the costs or the health gains \[[@CR8]\]. The economic evaluation was initially designed as a cost-effectiveness analysis (CEA) \[[@CR8]\], with incremental costs per case of Down's syndrome missed by MLPA. In case of comparable diagnostic accuracy for the detection of Down syndrome, a cost-utility analysis (CUA) was considered the appropriate economic framework, calculating the difference in costs in relation to differences in health-related quality of life \[[@CR8]\]. If differences in quality of life between the strategies were also absent, a cost-minimization analysis (CMA) was carried out. CMA implies that the preferred strategy from the societal perspective is the one with lowest costs, since health effects are equal \[[@CR8]\]. We did not include a do-nothing strategy, since the target population is eligible for karyotyping.

Health-related quality of life {#Sec7}
------------------------------

Alongside the clinical MAKE study we assessed health-related quality of life (HRQoL) in two groups: group 1 having karyotyping and group 2 having MLPA. Included were women with the indications maternal age, increased risk following the findings of prenatal screening for Down syndrome and parental anxiety. We used the MOS SF-36 health survey, measuring overall mental and overall physical health. Mental and physical health were measured before amniocentesis and at day 63 following amniocentesis, since the SF-36 focuses on health status during the preceding 4 weeks. Overall mental and physical health was calculated according to accepted scoring algorithms \[[@CR12]\].

Costs {#Sec8}
-----

We distinguished the costs of the MLPA and karyotyping strategies in two components; short- and long-term costs. The first component, the short-term costs, comprises all societal costs that occur between amniocentesis and parents' decision to terminate or continue pregnancy. These costs consist of the costs of the diagnostic tests and other costs. The second component consists of the long-term costs, i.e. all societal costs that occur between parents' decision to terminate or continue pregnancy and lifetime costs. Although it is controversial whether the costs associated with chromosomal abnormalities should be included in this type of analysis \[[@CR13]--[@CR15]\], we decided to display the impact of missed chromosomal abnormalities on long-term costs.

Short-term and long-term costs were further distinguished in direct medical costs (i.e. laboratory costs, additional in-hospital medical costs during follow-up), direct non-medical costs (patient expenses, e.g. patient time and travel costs) and indirect costs (societal costs due to absence from work) \[[@CR8]\].

The main outcome parameters were the difference in short-term costs between the MLPA and TKT strategies, the long-term cost difference, and the overall cost difference.

Short-term costs {#Sec9}
----------------

The short-term costs consisted of the costs associated with performing MLPA and/or karyotyping and other costs related to the testing process. Direct medical costs of performed tests were calculated as actual volumes of resource use multiplied by the costs per unit of resource. Number and type of tests performed were recorded in the clinical record form or obtained by observation or questionnaire. We used direct observations and measurements of working time, materials, and depreciation costs of equipment to quantify resource use associated with MLPA. Costs per units were obtained from a university hospital's budgetary and accounting system and were subsequently applied to the resource use observed in a small and large centre. The costs per units reflected the costs of staff, materials, equipment, housing and departmental and hospital overheads.

The other short-term costs consisted of additional diagnostic tests, costs of genetic counseling in case a chromosomal abnormality was detected, and travel costs. Use of additional diagnostic tests was recorded in the case record form. In case of a chromosomal abnormality, we assumed parents visited the hospital twice for genetic counseling \[50% of cases by performed by gynecologists (trisomies 13, 18 and 21) and 50% seen by clinical geneticists and social workers (all other chromosomal abnormalities)\]. Travel costs per client were based on the average travel distance to hospitals \[[@CR16]\]. The unit costs of direct non-medical costs were based on Dutch guidelines \[[@CR16], [@CR17]\]. Short-term indirect costs did not occur.

Study-specific costs as well as costs not associated with diagnostic test performance (prenatal test counseling, amniocentesis, ultrasound, sample transport, procedure-related miscarriages) were expected to be independent of the type of diagnostic test, and were therefore excluded from analysis. Given the time horizon no discount rate is used. When necessary, costs were updated to the 2007 price level by using the Dutch Consumer Price Index \[[@CR18]\].

Long-term costs {#Sec10}
---------------

The long-term costs were defined as the costs associated chromosomal abnormalities and consisted of (1) incremental costs for a child having a chromosomal abnormality and (2) costs for parents of the affected child. We first categorized chromosomal abnormalities according to clinical relevance: severe consequences and other chromosomal abnormalities leading to severe fetal morbidity or mortality (category I: includes trisomies 13, 18 and 21); uncertain consequences (including sex chromosomal abnormalities) and de novo balanced chromosomal abnormalities which can lead to 6% mental retardation and/or congenital abnormalities \[[@CR19]\] (category II); and no consequences including inherited chromosomal abnormalities and chromosomal abnormalities of known clinical irrelevance (category III). For category I chromosomal abnormalities, we used an incremental lifetime cost of €200.000 per child \[[@CR20]--[@CR22]\], a weighted average of the costs of trisomies 13, 18 and 21 adjusted for the average costs per child. The costs of a category II abnormality were estimated to be 6% of the costs of a child with category I abnormality. Category III abnormalities were considered not to induce extra costs.

Productivity loss due to absence from work in case of a chromosomal abnormality was estimated according to the friction cost method \[[@CR16]\]. In case the pregnancy was terminated, both parents were considered to have a sick leave; on average 6 weeks for mothers and 2 weeks' leave for partners. If the parents decided to continue the pregnancy in case of a severe chromosomal abnormality, the productivity loss exceeded the friction period (22 weeks) and no extra costs beyond the friction period were included. Assuming pregnant women to have on average one child, working 26 h/week and aged of 25--44 years, the productivity loss is €33.60/h lost \[[@CR18]\]. Assuming the partner to be male, aged 25--44 years old and working fulltime, his productivity loss is on average €40.86/h lost \[[@CR18]\].

Sensitivity analysis {#Sec11}
--------------------

We used a sensitivity analysis to test the robustness of the cost differences. We varied the major assumptions underlying the cost-effectiveness model for the following parameters: (1) proportion of failed MLPA results, according to the 5th and 95th percentiles of the observed failure rate; (2) only samples with clear amniotic fluid are analyzed with MLPA, all other samples with karyotyping; (3) the proportion of terminated pregnancy in case of category I chromosomal abnormalities varies from 70--80%); (4) women are allowed individual choice: 50% of women opts for MLPA and 50% for karyotyping \[[@CR23]\]; (5) sample throughput based on a small centre (*n* = 286) and a large centre (*n* = 1,153); (6) one nationwide MLPA laboratory; (7) all samples are analyzed with both MLPA and karyotyping. Parameters 1 and 5 are subject to different laboratory practices. Parameter 3 might relate to societal trends, counseling style or the counselor's medical specialty \[[@CR24]\]. Parameters 2, 4, 6, and 7 might change following changes in prenatal diagnostic protocols or guidelines.

Statistical analysis {#Sec12}
--------------------

Data were recorded and analyzed by using statistical software (SPSS version 16.0; SPSS, Chicago, Illinois). Observed data described with descriptive statistical measures; medians with range, or mean differences with 95% confidence intervals (CIs). Due to skewness of cost data, the 95% CI of the mean short-term, long-term and overall cost differences between the strategies were obtained with the nonparametric bootstrap method, based on 10,000 bootstrap samples \[[@CR25]\]; *p* value less than 0.05 (two-tailed) was considered statistically significant.

Results {#Sec13}
=======

Patients and test results {#Sec14}
-------------------------

Between March 2007 and October 2008 we included 4,585 consecutively pregnant women. Patient and procedural characteristics are displayed in Table [1](#Tab1){ref-type="table"}. In 4,484/4,585 samples (97.8%) MLPA and karyotyping were concordant, showing normal results in 4,387/4,585 (95.7%) and aneuploidy in 98/4,585 (2.1%). Discordant results were found in 26/4,585 (0.6%) samples, representing an abnormal karyotype undetected by MLPA. All aneuploidies of chromosomes 13, 18, 21 and non-mosaic X and Y were also detected by MLPA. MLPA, by design, could not detect three severe chromosomal abnormalities other than trisomies 13, 18, 21. In 75 cases (1.6%) the MLPA test result failed. Karyotyping failed in one of these 75 cases (0.02%). Diagnostic accuracy of MLPA was comparable (non-inferior) to karyotyping (1.0 95% CI 0.999--1.0). Sensitivity and specificity for the detection of trisomies 13, 18, 21, X and Y were 100% (95% CI 96--100%) and 100% (95% CI 99.9--100%), respectively \[[@CR11]\]. There were neither statistical nor clinically relevant differences in HRQoL. Summary physical and mental health scores between people receiving a karyotype or MLPA did not differ (mean difference 0.31; 95% CI −3.06 to 2.44; *p* 0.82 and mean difference 1.91 95% CI −1.15 to 4.99; *p* 0.22, respectively) (see Table S1). Therefore, we considered cost-minimization analysis the appropriate framework.Table 1Baseline and procedural characteristicsMedian age (years) (5th to 95th%)38.1 (31.8 to 42.4)Indication (%) Advanced maternal age3,464 (75.6) Increased risk following prenatal screening1,074 (23.4) Anxiety47 (1.0)Median gravidity (5th to 95th%)2 (1 to 5)Median parity (5th to 95th%)1 (0 to 3)Median gestational age (weeks + days) (5th to 95th%)16 +1 (14 + 6 to 17 + 4)Withdrawn amniotic fluid (median) (5th to 95th%)20 ml (16.0 to 20.0)Color of amniotic fluid Clear/yellow4,467 (97.4%) Red/brown/turbid/green118 (2.6%)Cell pellet color White3,923 (85.6%) Trace of blood381 (8.3%) Red/brown/green, yellow, turbid281 (6.1%)Amniotic fluid for MLPA (median) (5th to 95th%)4 ml (2.0 to 8.0)

Short-term costs {#Sec15}
----------------

The test costs of the MLPA test performed in duplicate were €344,60 per sample (65% direct and 35% overhead costs), while the costs of karyotyping was €668,00 per sample (74% direct and 26% overhead costs). Table [2](#Tab2){ref-type="table"} details the volumes of resource use, unit costs per resource and the total short-term costs.Table 2Short-term costs: resource use and costs between amniocentesis and the decision to continue or terminate pregnancyResource useMLPA strategy (*n* = 4,585)% of total costs MLPAKaryotyping strategy (*n* = 4,585)% of total costs karyotypingUnit costsNoNoEuro*Direct costs in the hospital*Primary procedure MLPA4,58587.3%00.0%€344.60 Karyotyping00.0%4,58593.98%€668.00Additional diagnostic tests Karyotyping1736.4%00.0%€668.00 FISH50.22%110.27%€809.00Additional diagnostic tests in case of CA Parental karyotyping00.0%440.90%€668.00 DNA and/or biochemical investigation00.0%30.09%€934.00 Ultrasound examination (type II)220.79%340.68%€653.00Outpatients visit in case of CA Consult gynecologists (2 visits)350.48%350.26%€246.00 Consult clinical geneticist and social worker (2 visits)634.82%893.78%€1,385.00*Direct medical costs outside the hospital* Travel costs in case of CA (2 visits to hospital)980.05%1240.04%€9.48Total short-term costs per sample€394.93€710.65*CA* chromosomal abnormality

In the MLPA strategy, 173 subsequent karyotyping were performed because MLPA failed (*n* = 75) or because MLPA showed a chromosomal abnormality and inheritance patterns needed to be examined (*n* = 98). Repeat amniocentesis did not occur. MLPA was repeated in 1.6% (5th to 95th percentile 1.3--2.1%) due to an inconclusive result. Five subsequent FISH analyses were done: three because MLPA showed a deletion on a single probe and the laboratory wished to exclude a sub-microscopic deletion, and two for a mosaic chromosome pattern (combined mosaic pattern of Turner and Down syndrome and a mosaic pattern for Turner syndrome and a normal female cell line). In 22 cases in the MLPA strategy and 34 cases in the karyotyping strategy, advanced ultrasound examination was required to exclude other severe congenital abnormalities (e.g. cardiac abnormalities) in the presence of the chromosomal abnormality to support the decision to continue or terminate the pregnancy.

In the karyotyping strategy, 11 subsequent FISH analysis were performed for various reasons; additional information on the grade of mosaicism (mosaic pattern Turner and Down syndrome, mosaic pattern of Turner syndrome) (*n* = 2), for marker chromosomes (*n* = 4), de novo unbalanced chromosomal abnormalities (*n* = 2), a chromosomal abnormality which appeared to be a normal variant (*n* = 2), and for a mosaic pattern of male and female karyotype which was determined to be a culture artefact (*n* = 1). In the latter case, biochemical investigation on amniotic fluid was also carried out to determine the testosterone/FSH ratio and karyotyping was repeated in a postnatal sample. In 24 cases parental karyotyping was performed to address the origin of the chromosomal abnormality (inherited or de novo). To assess the consequences of the de novo interstitial deletion, MLPA on subtelomeres and a genomic micro array was carried out. One karyotype failed due to contaminated amniotic fluid (blood and clots). Repeat amniocentesis was offered but the prospective parents declined.

The median short-term costs per sample, i.e. from amniocentesis until the decision to continue or terminate pregnancy, were €344.60 (range €344.60--3.216.08) for the MLPA strategy and €668.00 (range €668.00--4.669.48) for the karyotyping strategy. The short-term costs of the MLPA strategy were on average €315.68 (bootstrap 95% CI €315.63--315.74) lower than the karyotyping strategy (−44.4%).

Long-term and total costs {#Sec16}
-------------------------

Table [3](#Tab3){ref-type="table"} displays the main volumes of resource use, the unit costs per resource use and the long-term costs following the decision to continue or terminate pregnancy. Seventy-six pregnancies in the MLPA strategy (72 clinically severe, 4 clinically uncertain, 0 clinically not relevant) and 79 pregnancies in the karyotyping strategy (74 clinically severe, 5 clinically uncertain, 0 clinically not relevant) were terminated (Table S2). In two pregnancies, postnatal karyotyping was carried out to confirm the prenatal diagnosis (mosaic marker chromosome and mosaic Turner).Table 3Long-term costs: resource use and costs after the decision to terminate or continue pregnancyLong-term consequencesMLPA strategy (*n* = 4,585)% of total costsKaryotyping strategy (*n* = 4,585)% of total costsUnit costsTerminated pregnancies for detected CA Total termination of pregnancy762.2%792.5%€1,314,00 Clinically severe CA (T21/13/18 and other)7274-- Clinically uncertain CA (X/Y and other)45-- Travel costs760.01%790.01%€4,74Productivity loss for terminated pregnancies with CA7611.2%7912.9%€6,730,38Continued pregnancies for detected CA Clinically severe CA (T21/13/18 and other)1356.8%1468.1%€200.000,- Clinically uncertain CA (X/Y and other)92.4%144.1%€12.000,- Clinically not relevant CA (other)00.0%170.0%-- Confirmation of prenatal cytogenetic result after birth00.0%20.04%€739,72 Productivity loss for continued pregnancies with severe CA139.6%1411.6%€33.940,- Productivity loss for continued pregnancies with uncertain CA90.4%140.7%€2,036,40 Productivity loss for continued pregnancies with not relevant CA00.0%170.0%--Costs for undetected chromosomal abnormalities Other clinically severe CA313.1%00.0%€200.000,- Other clinically uncertain CA61.6%00.0%€12.000,- Other clinically not relevant CA170.0%00.0%-- Productivity loss for undetected severe CA32.4%00.0%€36.861,- Productivity loss for undetected uncertain CA60.3%00.0%€2.211,66 Productivity loss for undetected not relevant CA170.0%00.0%€0,00Total long-term costs per sample€997,85€896,19*CA* chromosomal abnormality

The median long-term costs per sample, i.e. from the decision to continue or terminate pregnancy onwards, were €0.00 (range €0.00--233,940.00) for the MLPA strategy and €0.00 (range €0.00 to 237,000.08) for the karyotyping strategy (Table [2](#Tab2){ref-type="table"}). The long-term costs of the MLPA strategy were on average €76.42 higher compared to the karyotyping strategy (bootstrap 95% CI €71.32--81.52; +8.6%) per sample.

The total costs, including both short- and long-term costs, were median €344.60 (range €344.60--237,000.08) for the MLPA strategy and €668.00 (range €668.00--238,956.48) for the karyotyping strategy. The total cost difference was €240.13 (bootstrap 95% CI €235.02--€245.23) in favor of MLPA (cost reduction −14.9%).

Sensitivity analysis {#Sec17}
--------------------

Table [4](#Tab4){ref-type="table"} displays the results of the sensitivity analyses. Total MLPA costs were sensitive to the following parameters: the proportion of women deciding to terminate pregnancy, women allowed individual choice, the level of sample throughput, and performing both MLPA and karyotyping. Except for the combined MLPA and karyotyping strategy, the total costs difference remained in favor of MLPA.Table 4Sensitivity analysis: impact of parameters varied on short-term, long-term and total MLPA costs per sample (US dollars, %) compared to baseline; and impact on the total (short term and long term) cost difference of MLPA and karyotypingParameter variedShort-term costs of MLPA strategy per sample \[€ (% change)\]^a^Long-term costs of MLPA strategy per sample \[€ (% change)\]^a^Total cost of MLPA strategy \[€ (% change)\]^a^Baseline strategy394.93 (n.a.)997.85 (n.a.)n.a.Failure rate 1.31%392.75 (−0.6%)997.85 (−)−2.19 (−0.2%) 2.05%397.70 (+0.7%)997.85 (−)+2.77 (+0.2%)Only samples with clear amniotic fluid analyzed with MLPA401.44 (+1.7%)997.85 (−)+6.50 (+0.5%)% TOP if severe CA 80%394.93 (−)1,195.18 (+20.8%)+197.33 (+14.2%) 70%394.93 (−)1,638.32 (+64.2%)+640.48 (+48.7%)Women are allowed individual choice552.18 (+39.8%)971.65 (−2.8%)+131.05 (+9.4%)Sample throughput 286 samples/year500.55 (+26.7%)997.85 (−)+105.62 (+7.6%) 1,153 samples/year374.94 (−5.1%)997.85 (−)−19.99 (−1.4%)One nationwide MLPA laboratory294.68 (−29.6%)997.85 (−)−100.25 (−7.20%)All samples analyzed with MLPA and karyotyping660.85 (+167.3%)896.19 (−10.1%)+599.19 (+43.02)*CA* chromosomal abnormality, *TOP* termination of pregnancy^a^Change compared to baseline

Discussion {#Sec18}
==========

We evaluated the cost-effectiveness of two prenatal diagnostic test strategies: MLPA and karyotyping. Diagnostic accuracy of MLPA was comparable to karyotyping and health-related quality of life was equal between strategies. For the complete testing process, the MLPA strategy lead to a 14.9% cost reduction per amniotic fluid sample for women with relatively low-risk indications (−44.4% on the short and +8.6% on the long term).

Our study has several limitations. Firstly, we used the data of the nationwide prospective MAKE study which prioritized karyotyping, since at least 12 ml of amniotic fluid was required. The failure rate of MLPA (1.6%) may be lower when MLPA is applied as stand-alone technique since MLPA requires at least 1--2 ml. Sensitivity analysis, however, showed that variations in failure rate had little impact on the overall cost difference. Secondly, we were unable to measure quality of life for women who decided to continue or terminate pregnancy in case of a chromosomal abnormality and in parents with rare prenatally undetected fetal chromosomal abnormalities. However, diagnostic accuracy was high and comparable; we can speculate that the decision to continue or terminate pregnancy in case of a chromosomal abnormality is the same, regardless of the diagnostic test used. The three severe chromosomal abnormalities undetected by MLPA may result in a decreased quality of life at the individual level but not in differences at the group level. Thirdly, we did not adjust the costs associated with pre-test counseling. We expect that targeted testing reduces complex counseling issues and is therefore less costly. Furthermore, three FISH analysis were done following MLPA to exclude a sub-microscopic deletion. If MLPA is implemented as a stand-alone test to detect trisomies 13, 18, 21 X and Y, our research group advises to neglect the interpretation of the quantification of single probes. Taking this into account, the cost reduction of MLPA compared to karyotyping may be even larger than we estimated. Finally, costs were based on Dutch health care costs, which might differ from costs in other countries. That does not imply that the outcome of MLPA being the strategy with lowest costs is not externally valid for other countries. Hence, overall cost differences between countries do affect the absolute cost differences, but do not affect the ordering of strategies in terms of costs.

Compared to other RAD techniques, MLPA and quantitative fluorescent polymerase chain reaction (QF-PCR) are both suitable techniques for high-throughput testing at lower costs compared to fluorescent in situ hybridization (FISH) \[[@CR26]\]. A cost analysis of QF-PCR and revealed that both tests are sensitive to sample throughput and staff skill-mix FISH (2003) \[[@CR26]\]. For laboratories with a throughput of 1,000 samples per annum, karyotyping is the most expensive test to perform, with FISH and Q-PCR calculated to incur approximately half the direct test costs of karyotyping \[[@CR26]\]. However, these studies did not include long-term costs. Due to differences in methodology, a full comparison with our study is impossible.

Costs differences were insensitive to variations in failure rate, or using MLPA on contaminated amniotic fluid samples. However, the costs of MLPA proved sensitive to the proportion of terminated pregnancies and therefore to societal trends, but this is unlikely to affect the overall cost difference. Furthermore, the costs of the MLPA strategy were sensitive to sample throughput as well as the concentration of MLPA analyses in one nationwide centre. This shows that the costs and cost differences depend on the way care is organized. Since the impact of concentration on costs was larger than the impact of higher throughput, we recommend the use of one (or several) nationwide MLPA laboratories. Our study also shows that a combined strategy of MLPA followed by karyotyping is rather inefficient. Costs are considerably increased without any gain in diagnostic accuracy or health-related quality of life compared to the karyotyping only strategy.

The provision of a rapid, unambiguous and a low cost result is an incentive to implement MLPA. Successful implementation, however, also requires the support of pregnant women. If one supports individualized choice for principle or other reasons \[[@CR27]\], one could argue that the decision to either obtain as much cytogenetic information as possible versus a rapid but specific result on the most common chromosomal abnormalities is most appropriately made by individuals who will bear the responsibility for raising the child. Our study shows that allowing individualized choice---assuming that 50% chooses karyotyping and 50% chooses MLPA \[[@CR23]\]---also has large impact on costs, reducing the cost difference of €240 per sample to €83 per sample). While individual choice as strategy is less efficient than a uniform strategy in which every patient would receive MLPA, the overall cost reduction is still in favor of MLPA over the current karyotyping strategy. One could argue that offering a choice between the tests meets most individual needs and wishes, and thereby might outweigh the cost difference. In a discrete choice experimentation \[[@CR28]\], women valued the comprehensive information of karyotyping at £791 and the simple and quick information of a Down only test at £690. This supports our idea that the option to choose may outweigh the previously mentioned efficiency loss of €240 per sample to €83 per sample.

Conclusion {#Sec19}
==========

In summary, MLPA is able to detect trisomies 13, 18, 21, X and Y with comparable diagnostic accuracy \[[@CR10], [@CR29], [@CR30]\] and without adverse effect on quality of life at considerably lower costs for the complete testing process. We conclude that MLPA is the preferred strategy and recommend substitution of karyotyping for MLPA for relatively low-risk indications. Future research should be done to evaluate which RAD technique delivers best 'value for money', to estimate the cost-effectiveness of this RAD technique on chorionic villus biopsy, and to evaluate the most advantageous organization for the optimal RAD technique.
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On behalf of the MLPA and karyotyping (MAKE) study group. Members of the MAKE study group are given in the Appendix.
